-
ACEGEN: Reinforcement learning of generative chemical agents for drug discovery
Authors:
Albert Bou,
Morgan Thomas,
Sebastian Dittert,
Carles Navarro RamÃrez,
Maciej Majewski,
Ye Wang,
Shivam Patel,
Gary Tresadern,
Mazen Ahmad,
Vincent Moens,
Woody Sherman,
Simone Sciabola,
Gianni De Fabritiis
Abstract:
In recent years, reinforcement learning (RL) has emerged as a valuable tool in drug design, offering the potential to propose and optimize molecules with desired properties. However, striking a balance between capabilities, flexibility, reliability, and efficiency remains challenging due to the complexity of advanced RL algorithms and the significant reliance on specialized code. In this work, we…
▽ More
In recent years, reinforcement learning (RL) has emerged as a valuable tool in drug design, offering the potential to propose and optimize molecules with desired properties. However, striking a balance between capabilities, flexibility, reliability, and efficiency remains challenging due to the complexity of advanced RL algorithms and the significant reliance on specialized code. In this work, we introduce ACEGEN, a comprehensive and streamlined toolkit tailored for generative drug design, built using TorchRL, a modern RL library that offers thoroughly tested reusable components. We validate ACEGEN by benchmarking against other published generative modeling algorithms and show comparable or improved performance. We also show examples of ACEGEN applied in multiple drug discovery case studies. ACEGEN is accessible at \url{https://github.com/acellera/acegen-open} and available for use under the MIT license.
△ Less
Submitted 3 June, 2024; v1 submitted 7 May, 2024;
originally announced May 2024.
-
Large-scale Pretraining Improves Sample Efficiency of Active Learning based Molecule Virtual Screening
Authors:
Zhonglin Cao,
Simone Sciabola,
Ye Wang
Abstract:
Virtual screening of large compound libraries to identify potential hit candidates is one of the earliest steps in drug discovery. As the size of commercially available compound collections grows exponentially to the scale of billions, brute-force virtual screening using traditional tools such as docking becomes infeasible in terms of time and computational resources. Active learning and Bayesian…
▽ More
Virtual screening of large compound libraries to identify potential hit candidates is one of the earliest steps in drug discovery. As the size of commercially available compound collections grows exponentially to the scale of billions, brute-force virtual screening using traditional tools such as docking becomes infeasible in terms of time and computational resources. Active learning and Bayesian optimization has recently been proven as effective methods of narrowing down the search space. An essential component in those methods is a surrogate machine learning model that is trained with a small subset of the library to predict the desired properties of compounds. Accurate model can achieve high sample efficiency by finding the most promising compounds with only a fraction of the whole library being virtually screened. In this study, we examined the performance of pretrained transformer-based language model and graph neural network in Bayesian optimization active learning framework. The best pretrained models identifies 58.97% of the top-50000 by docking score after screening only 0.6% of an ultra-large library containing 99.5 million compounds, improving 8% over previous state-of-the-art baseline. Through extensive benchmarks, we show that the superior performance of pretrained models persists in both structure-based and ligand-based drug discovery. Such model can serve as a boost to the accuracy and sample efficiency of active learning based molecule virtual screening.
△ Less
Submitted 20 September, 2023;
originally announced September 2023.
-
A Transformer-based Generative Model for De Novo Molecular Design
Authors:
Wenlu Wang,
Ye Wang,
Honggang Zhao,
Simone Sciabola
Abstract:
In the scope of drug discovery, the molecular design aims to identify novel compounds from the chemical space where the potential drug-like molecules are estimated to be in the order of 10^60 - 10^100. Since this search task is computationally intractable due to the unbounded search space, deep learning draws a lot of attention as a new way of generating unseen molecules. As we seek compounds with…
▽ More
In the scope of drug discovery, the molecular design aims to identify novel compounds from the chemical space where the potential drug-like molecules are estimated to be in the order of 10^60 - 10^100. Since this search task is computationally intractable due to the unbounded search space, deep learning draws a lot of attention as a new way of generating unseen molecules. As we seek compounds with specific target proteins, we propose a Transformer-based deep model for de novo target-specific molecular design. The proposed method is capable of generating both drug-like compounds (without specified targets) and target-specific compounds. The latter are generated by enforcing different keys and values of the multi-head attention for each target. In this way, we allow the generation of SMILES strings to be conditional on the specified target. Experimental results demonstrate that our method is capable of generating both valid drug-like compounds and target-specific compounds. Moreover, the sampled compounds from conditional model largely occupy the real target-specific molecules' chemical space and also cover a significant fraction of novel compounds.
△ Less
Submitted 22 October, 2022; v1 submitted 17 October, 2022;
originally announced October 2022.